Shilpa Medicare is a vertically integrated specialty pharmaceutical company operating across three divisions: API (including CDMO, oncology, and peptides), formulations (complex generics, 505(b)(2), and a first-in-class NCE), and biologics (biosimilars, ADC, and novel biological entities). In Q1 FY27, the API division delivered INR260 crore revenue, up 15% year on year, formulations grew 100% to INR198 crore, and biologics rose 42% to INR52 crore, with overall revenue up 43% and EBITDA margin at 30%. The company sits in a niche where few Indian players combine small-molecule synthesis, large-molecule development, and integrated ADC manufacturing (mAb, payload, linker, and conjugation) in one platform. Its gross margin of 71% and sustained EBITDA above 28% over the past four quarters indicate that the business is already operating well above the average 13-15% typical of generic pharma, reflecting the complexity and limited competition of its chosen product portfolio.
The durability of these economics rests on multiple barriers that are visible in management's disclosures. The company is an exclusive supply partner for Unicycive's NCE with a dedicated commercial block, illustrating customer qualification and switching costs inherent in CDMO relationships. Rotigotine transdermal patch, which received EMA approval in Q3 FY26, is a complex dosage form with very few generic players, and NorUDCA, the first NCE launched in India, uses a differentiated mechanism targeting liver enzymes. Integration from API through to finished formulation means captive consumption of more than 50% of its own API, capturing margin at each step. The ADC facility is described as one of a kind in India, and the biologics division offers clone-to-fill-finish capabilities, which take years to replicate. These features point to a business that can maintain pricing power and margin resilience through cycles, not a commodity API manufacturer.
The inflection is now, as a multi-year capex cycle converts into revenue without major incremental investment. Several committed milestones land within the 18-24 month window: the peptide large-scale manufacturing block commissions by end FY27, the new oncology API block is expected in FY27, and the integrated ADC suite will be operational. Commercially, Aflibercept is set to launch in India in FY27, Rotigotine in the US in FY28, Nivolumab in India in FY28, and three late-stage NCE CDMO programs are slated to commercialize in FY28. NorUDCA global Phase 2 studies begin in FY27, and the first ADC biosimilar enters human studies in FY27. By FY28, the formulations and biologics divisions should contribute a significantly larger share of revenue than the roughly 50% they represented in FY26, while the API division grows steadily on the back of new oncology product validations and peptide capacity.
Management's track record is mixed but improving, with some solid deliveries and notable slips. NorUDCA was launched in Q3 FY26 as earlier guided, Rotigotine received EMA approval in Q3 FY26, and Unicycive's PDUFA date is set for June 2026, matching the earlier FY27 commercialization expectation. However, the albumin Phase III start was pushed from Q1 FY26 to later, and US FDA inspection for the Jadcherla facility remains pending after observations. The Q1 FY27 results show the company is now harvesting: adjusted ROCE improved to 12.5% (18.3% excluding biologics and NBE) from 8.8% in FY25, and net debt to EBITDA has compressed from 6.7 times three years ago to 1.3 times. Capital expenditure is being funded from internal accruals, with no significant new capex planned beyond the ongoing peptide and oncology blocks, and management has indicated the reinvestment phase is largely behind it.
The quantified earnings path is visible: FY26 EBITDA was INR445 crore at 29% margin, and Q1 FY27 annualizes to roughly INR556 crore at 30% margin without any contribution from new launches. With Aflibercept, Rotigotine, and the NCE CDMO commercializations adding through FY28, and licensing income expected to hold at around INR150 crore per year, EBITDA margin can move toward the 35% long-term target as operating leverage continues. The primary watchpoint is execution on the peptide and oncology block commissioning timelines, and the regulatory outcome for Unicycive's refiling, which will validate the CDMO relationship. A second risk is partner-dependent NCE programs, where delay is outside management's control. The tension between sluggish non-captive API growth in earlier quarters and acceleration in Q1 FY27 is resolved by the fact that captive consumption and new capacity are now driving volume, while the formulation and biologics mix is lifting blended margins structurally, not just cyclically.
companyname: Shilpa Medicare Limited ticker: SHILPAMED sector: Pharmaceuticals - APIs, Formulations, Biologics, CDMO Shilpa Medicare Limited is an Indian pharmaceutical company, incorporated in 1987 and headquartered in Raichur, Karnataka. It operates across three vertically integrated segments: Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDF), and Biologics. The company also offers Contract Development and Manufacturing Organization (CDMO) services spanning small mo...
Read the full report →capex, margin expansion, regulatory approval, new product segment
No guidance
mixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Shilpa Medicare Limited and 4,900+ companies.
5-day free pass. No card required.